Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranquillo: Phase 3 ritlecitinib in non-segmental vitiligo
jRCT2031220534Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing Ritlecitinib 50 mg with Placebo (2 arms). Started Dec 2022; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
Vitiligo
Beyond the preview
Go deeper on jRCT2031220534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220534.